IL36587A - Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions - Google Patents
Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactionsInfo
- Publication number
- IL36587A IL36587A IL36587A IL3658771A IL36587A IL 36587 A IL36587 A IL 36587A IL 36587 A IL36587 A IL 36587A IL 3658771 A IL3658771 A IL 3658771A IL 36587 A IL36587 A IL 36587A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- acid
- peripheral
- group
- compositions containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 5
- 230000001413 cellular effect Effects 0.000 title description 5
- 238000000034 method Methods 0.000 title description 3
- 238000006557 surface reaction Methods 0.000 title description 3
- 150000003222 pyridines Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000000903 blocking effect Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 230000002093 peripheral effect Effects 0.000 description 15
- 206010003445 Ascites Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 9
- 241001061127 Thione Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 150000008427 organic disulfides Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3487370A | 1970-05-05 | 1970-05-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL36587A0 IL36587A0 (en) | 1971-08-25 |
| IL36587A true IL36587A (en) | 1977-10-31 |
Family
ID=21879128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL36587A IL36587A (en) | 1970-05-05 | 1971-04-11 | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions |
Country Status (9)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152439A (en) * | 1978-01-12 | 1979-05-01 | Davide R. Grassetti | Stimulant and antidepressant agents |
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| DE3508666A1 (de) * | 1985-03-12 | 1986-09-18 | Hoechst Ag, 6230 Frankfurt | Heterocyclische disulfide und ihre anwendung als immunmodulatoren |
| WO1999007368A1 (en) * | 1997-08-05 | 1999-02-18 | Grassetti Davide R | Antimutagenic agents |
| US8163776B2 (en) | 2001-01-10 | 2012-04-24 | Grassetti Family Trust | Method of immunomodulation using thione-forming disulfides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH69A (fr) * | 1889-01-09 | Charles Humbert Fils | Nouveau système de cadran lumineux pour montres de poche, pendules, horloges publiques, etc. | |
| CH70A (fr) * | 1888-11-15 | 1889-01-09 | Louis Carpano | Fraises à arrondir les roues d'horlogerie |
| CH71A (de) * | 1888-11-15 | 1889-06-13 | Th Hunziker | Apparat zum Absticken verlängerter Nädlinge für Handstickmaschinen |
| GB582638A (en) * | 1944-07-05 | 1946-11-22 | Glaxo Lab Ltd | A new anti-bacterial pyridine derivative and salts thereof |
| FR1265863A (fr) * | 1959-05-04 | 1961-07-07 | Olin Mathieson | Fongicides complexes contenant du molybdène utilisés notamment en agriculture |
| FR6075M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1965-09-20 | 1968-06-04 | ||
| GB1190268A (en) * | 1966-05-12 | 1970-04-29 | Nyegaard & Co As | Pyridine Derivatives |
| ZA703779B (en) * | 1969-06-12 | 1972-01-26 | Ici Ltd | Pesticidally active compounds and compositions containing them |
-
1971
- 1971-04-11 IL IL36587A patent/IL36587A/en unknown
- 1971-04-19 PH PH12380A patent/PH12181A/en unknown
- 1971-04-22 BE BE766123A patent/BE766123A/xx not_active IP Right Cessation
- 1971-04-29 DE DE19712120995 patent/DE2120995A1/de active Pending
- 1971-05-04 ZA ZA712898A patent/ZA712898B/xx unknown
- 1971-05-05 CA CA112,199A patent/CA985170A/en not_active Expired
- 1971-05-05 NL NLAANVRAGE7106127,A patent/NL173242C/xx not_active IP Right Cessation
- 1971-05-05 GB GB1331771*[A patent/GB1416018A/en not_active Expired
- 1971-05-05 FR FR7116224A patent/FR2100631B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2120995A1 (de) | 1971-11-18 |
| GB1416018A (en) | 1975-12-03 |
| CA985170A (en) | 1976-03-09 |
| FR2100631A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-03-24 |
| IL36587A0 (en) | 1971-08-25 |
| NL7106127A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1971-11-09 |
| NL173242B (nl) | 1983-08-01 |
| BE766123A (fr) | 1971-09-16 |
| FR2100631B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-04-18 |
| PH12181A (en) | 1978-11-21 |
| NL173242C (nl) | 1984-01-02 |
| ZA712898B (en) | 1973-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MERRILL et al. | Clinical recognition and treatment of acute potassium intoxication | |
| Iseri et al. | Magnesium and potassium therapy in multifocal atrial tachycardia | |
| KEITH et al. | Some effects of potassium salts in man | |
| Grob et al. | Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate) | |
| Heath et al. | Quantitative aspects of iron deficiency in hypochromic anemia:(The parenteral administration of iron) | |
| Hopkins | Experimental lead poisoning in the baboon | |
| EP0697862A1 (en) | Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders | |
| GB2081094A (en) | The use of dithiocarbamic compounds in cancer therapy | |
| IL36587A (en) | Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions | |
| Schiffrin | Relationship between the parathyroid and the gastric glands in the dog | |
| Perlmutter et al. | Idiopathic hypoparathyroidism and Addison's disease | |
| US4378364A (en) | Postoperative treatment of carcinoma patients | |
| US4656178A (en) | Pharmaceutical composition possessing antiarrhythmic effect | |
| Melville et al. | General systemic effects and electrocardiographic changes following injections of digitalis glycosides into the lateral ventricle of the brain | |
| Cleghorn et al. | The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate) | |
| Berliner | The effect of calcium on the heart | |
| US2259492A (en) | Therapeutic preparation of bismuth and method of preparing same | |
| US4152439A (en) | Stimulant and antidepressant agents | |
| US2312195A (en) | Salts of dextro-ascorbic acid and method of preparing same | |
| Sugiura et al. | The influence of inorganic salts upon tumor growth in albino rats | |
| JOOS et al. | ELECTROCARDIOGRAPHIC CHANGES DURING REPLACEMENT TRANSFUSION: Special Reference to the Effects of Serum Electrolyte Disturbances | |
| GB2044265A (en) | Adenosine Triphosphate Metal Complexes, Processes for Their Preparation and Pharmaceutical Compositions Containing Them | |
| Dilling | Some pharmacological effects of lead | |
| Hashimoto | Transient change in the auriculoventricular condition following the injection of histamin | |
| McCrea et al. | The Action of Mercury upon the Heart |